Exploratory multicenter observational study to assess the outcome of infants with perinatal SARS-COV-2 infection and its link with the NO pathway: the minipuberty hypothesis FRESH-PEF73964-en Vincent PREVOT Exploratory multicenter observational study to assess the outcome of infants with perinatal SARS-COV-2 infection and its link with the NO pathway: the minipuberty hypothesis miniNO-COVID FRESH-PEF73964-en 73964 FRESH-PEF73964 NCT04952870 Laurent STORME Vincent PREVOT CENTRE HOSPITALIER UNIVERSITAIRE DE LILLE (CHU) Epidemiology France Portal (PEF) EUROPEAN COMMISSION RESEARCH null Endocrinology Neurology Paediatrics Endocrine, nutritional or metabolic diseases Mental, behavioural or neurodevelopmental disorders Diseases of the nervous system COVID-19 To compare the follicle stimulating hormone (FSH) plasma concentrations measured at the postnatal age of 3 months between the three matched (on gestational age at birth, postnatal age and respiratory failure) newborn infants groups null France Germany Switzerland United Kingdom Greece Belgium Individuals Patients population Male Female Infant, Newborn (birth to 28 days) Infant (28 days to 2 years) o Newborn infants (24 to 41 weeks gestational age) or young infants (< 3 months) admitted at the maternity ward or at the Department of Neonatology at Jeanne de Flandre Hospital, CHU of Lille with perinatal COVID-19 infection defined by: o Antenatal COVID-19 infection: pregnant women with positive PCR test at any time of the pregnancy; o Post-natal COVID-19 infection: newborn or young infants (< 3 months) with positive PCR test in pharynx or stools as part of their treatment. o Newborn infants (24 to 41 weeks gestational age) or young infants (< 3 months) admitted at the maternity ward or at the Department of Neonatology at Jeanne de Flandre Hospital, CHU of Lille for severe cardiorespiratory diseases requiring inhaled NO treatment. o The control group without perinatal COVID-19 infection will be matched to thevtreatment group on gestational age at birth (± 2 weeks of gestation), on postnatal age (± 3 weeks) and respiratory failure. o No inclusion in another ante- or post-natal trial; o Written consents from both parents; Clinical data Biological data Other Through independent healthcare practitioners < 500 individuals Interview with the participant (including clinical) Converting or copying information into a structured record Observational Study Observational Study Case-control study Unknown Metadata-only access Access not yet planned